A mouse model of the oncogenic PAX5‐JAK2 translocation reveals promotion of aggressive B‐ALL not via transcriptional or epigenetic alterations, but via increased phosphorylation and activation of the JAK2 target STAT5. This evidence concerns the gene STAT5B and precursor B-cell acute lymphoblastic leukemia.